Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial

PURPOSE: To report population pharmacokinetic (PK) analysis of the phase 1 study (FPA144-001, NCT02318329) and to select a clinical dose and schedule that will achieve an empirical target trough concentration (C(trough)) for an anti-fibroblast growth factor receptor 2b antibody, bemarituzumab. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Hong, Liu, Lucy, Gao, Yuying, Ahene, Ago, Macal, Monica, Hsu, Amy W., Dreiling, Lyndah, Collins, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561547/
https://www.ncbi.nlm.nih.gov/pubmed/32965540
http://dx.doi.org/10.1007/s00280-020-04139-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561547/
https://www.ncbi.nlm.nih.gov/pubmed/32965540
http://dx.doi.org/10.1007/s00280-020-04139-4

Ejemplares similares